Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies
MEASURE DESCRIPTION
Percentage of adult patients (aged 18 or over) with metastatic colorectal cancer who have a KRAS or NRAS gene mutation for whom anti-EGFR monoclonal antibody therapy was not received
Relevance to Value Based Care
Clinical trials show the benefit of using EGFR inhibitors in treating metastatic colorectal cancer, either as monotherapy or in combination with other regimens, is limited to non-existent in patients with RAS-mutated tumors. Data strongly suggests patients with RAS mutations are better served with other therapies.
Numerator
Patients who did not receive an anti-EGFR monoclonal antibody therapy (G9844)
Denominator
Adult patients ≥ 18 years with an E/M visit during the reporting period, a diagnosis of metastatic colorectal cancer and who have a KRAS or NRAS gene mutation
Exclusion/Exceptions
None.
Scoring
CMS has removed the benchmark for this measure for 2024. Reporting this measure will earn 0 points, unless CMS develops benchmarks after submission.
RESOURCES